Background The use of natalizumab in multiple sclerosis (MS) may favour JC virus reactivation; this phenomenon is usually asymptomatic but can, albeit rarely, evolve into frank progressive multifocal leucoencephalopathy (PML). Methods JCV-specific CD8+ T lymphocytes were evaluated by flow cytometry over a 24-month period in 24 natalizumab-treated MS patients in whom JCV DNA was or was not detected in blood using quantitative real-time polymerase chain reaction; all these cases were asymptomatic. Results Perforin- and grazymes-containing VP-1-specific CD8+ T lymphocytes were reduced whereas CD107a-expressing cells were increased in JCV positive patients, suggesting an active degranulation of these cells; naïve CD8+ T lymphocytes were also decreased whereas memory cells were increased in patients in whom JCV reactivation was observed. Conclusion The presence of a CD8+ T lymphocyte-mediated effector immune response offers a greater insight into reactivation of JCV and its clinical sequelae, and may help the monitoring of patients on natalizumab therapy.
JC virus detection and JC virus-specific immunity in natalizumab-treated multiple sclerosis patients / R. Mancuso, M. Saresella, A. Hernis, I. Marventano, C. Ricci, S. Agostini, M. Rovaris, D. Caputo, M. Clerici. - In: JOURNAL OF TRANSLATIONAL MEDICINE. - ISSN 1479-5876. - 10:12(2012 Dec 11), pp. 248.1-248.10.
|Titolo:||JC virus detection and JC virus-specific immunity in natalizumab-treated multiple sclerosis patients|
|Parole Chiave:||Cell mediated immunity; MS; Natalizumab|
|Settore Scientifico Disciplinare:||Settore MED/04 - Patologia Generale|
|Data di pubblicazione:||11-dic-2012|
|Digital Object Identifier (DOI):||http://dx.doi.org/10.1186/1479-5876-10-248|
|Appare nelle tipologie:||01 - Articolo su periodico|